Peplin Discusses Results From AK Trial

Peplin reported preliminary results of an Australian- and New Zealand-based Phase IIa trial of PEP005, the company’s topical actinic keratosis (AK) therapy.

AKs are precancerous lesions caused by sun exposure that can develop into skin cancer.

The open-label, multicenter trial is designed to determine the optimal regime and evaluate the safety and efficacy of the drug when applied to a 25 square centimeter area of skin on the face and scalp.

The trial established the maximum tolerated dose at 0.025 percent applied daily for two consecutive days as a field-directed therapy, Peplin said.